Antigen News and Research

RSS

U.S. Patent Office issues Notice of Allowance to Antigen Express AE37 cancer vaccine

Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, announced today that Antigen Express has received a Notice of Allowance from the United States Patent Office relating to an application making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer vaccine.

4 Feb 2011

Researchers discover potential vaccine capable of reducing H. pylori colonization

A new study led by researchers at Rhode Island Hospital in collaboration with the University of Rhode Island and EpiVax. Inc, a privately owned vaccine development company in Providence, RI, has identified a potential vaccine capable of reducing colonization of Helicobacter pylori -- a known cause of gastritis, ulcer disease and cancer.

2 Feb 2011

Inovio publishes scientific paper detailing SynCon DNA vaccine preclinical study for prostate cancer

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of Inovio's SynCon DNA vaccine for prostate cancer targeting two antigens.

2 Feb 2011

Novel personalized therapy could treat metastatic melanoma and metastatic synovial cell sarcoma

Researchers have found that a novel form of personalized therapy that genetically engineers a patient's own anti-tumor immune cells to fight tumors could treat metastatic melanoma and metastatic synovial cell sarcoma, representing a potentially new therapeutic approach against these and other cancers.

1 Feb 2011

Researchers study peripheral blood Tregs as disease marker of gastric cancer

T-regulatory lymphocytes are a subset of T lymphocytes that are involved in the mechanism of immunotolerance to self- and allo-antigens. Activity of these cells is one of the mechanisms of immune evasion of tumors, which inhibits the antitumor activity of effector cells.

1 Feb 2011

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.

31 Jan 2011

North Shore-LIJ seeks patients with early-stage prostate cancer to participate in Phase I study

The North Shore-LIJ Health System Department of Radiation Medicine announced today it is seeking patients with early-stage prostate cancer to participate in a Phase I Research study.

29 Jan 2011

Preclinical data on Inovio’s intradermal electroporation delivery devices presented at Phacilitate Vaccine Forum

Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.

28 Jan 2011

Scientist identifies polymorphism that raises risk of poor outcomes in preterm infants

Researchers at Cincinnati Children's Hospital Medical Center have identified biomarkers of poor outcomes in preterm infants that may help identify new approaches to prevention.

28 Jan 2011

Pfenex receives $3.1 million SAIC sub-contract to develop malaria antigen

Pfenex today announced that Science Applications International Corporation has awarded Pfenex a sub-contract valued at $3.1 million to help develop a robust, scalable, cGMP ready production process for large scale production of full length Circumsporozoite protein from Plasmodium falciparum.

27 Jan 2011

FDA issues Complete Response letter for Avodart sNDA for reduction of prostate cancer risk

GlaxoSmithKline (GSK) today announced that the Company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the supplemental New Drug Application (sNDA) for Avodart® (dutasteride) for reducing the risk of prostate cancer in men at increased risk for the disease, defined as those who have had a prior negative biopsy due to clinical concern and have an elevated serum prostate-specific antigen (PSA).

27 Jan 2011

Diamyd Medical reports first quarter group total net sales of MSEK 144.5

Diamyd completed screening for US Phase III study in type 1 diabetes. The screening of patients for the US Phase III study, DiaPrevent, was completed, ending the recruitment campaign. More than 310 recently diagnosed type 1 diabetes patients between 10 and 20 years of age had, at the completion of screening, been enrolled in the study and received their first injection of the antigen-based therapy Diamyd® or placebo.

25 Jan 2011

Agenus enters research agreement with Memorial Sloan-Kettering Cancer Center

Agenus Inc. today announced it has entered into a research agreement with Memorial Sloan-Kettering Cancer Center (MSKCC) using Agenus' proprietary cancer vaccine technology.

24 Jan 2011

Researchers map complex choreography used by immune system's T cells to recognize pathogens

Researchers have for the first time mapped the complex choreography used by the immune system's T cells to recognize pathogens while avoiding attacks on the body's own cells.

21 Jan 2011

OriGene releases 1,500 mouse monoclonal antibodies

OriGene Technologies, Inc. has recently achieved a significant milestone in its quest for developing an assay for every human protein through the release of 1,500 mouse monoclonal antibodies under the TrueMAB brand. Each TrueMAB antibody is specifically developed with full-length human proteins produced in HEK293T cells and validated for critical research and diagnostic needs requiring improved antibody sensitivity and specificity.

21 Jan 2011

National Jewish Health issued method patent for desensitizing B cells

National Jewish Health has been issued a US patent claiming a method to desensitize B cells by inactivating antigen receptors on their surfaces. The method, discovered by John Cambier, PhD, Chairman of the Integrated Department of Immunology at National Jewish Health, holds promise for treatment of B-cell mediated diseases, such as lymphoma and leukemia, rheumatoid arthritis, lupus and rejection of organ transplants.

19 Jan 2011

Vaccine to prevent MRSA infections after bone and joint surgery

University of Rochester Medical Center orthopaedic scientists are a step closer to developing a vaccine to prevent life-threatening methicillin-resistant staphylococcus aureus (MRSA) infections following bone and joint surgery.

18 Jan 2011

Scientists demonstrate mechanism that explains why PSA levels promote prostate cancer

Researchers at the Duke Cancer Institute who have been studying prostate cancer cells for decades now think they know why PSA levels reflect cancer progression.

14 Jan 2011

T.A. Sciences receives US patent for TA-65 to tackle aging process

Telomerase Activation Sciences, today announced the issuance of U.S. Patent No. 7,846,904 to the Geron Corporation. The patent covers the use of certain compounds to upregulate telomerase expression in cells.